On the two electrophoretic forms of the human superoxide dismutase A in the homozygote SOD A1

Binding of a single zinc ion to one subunit of copper-zinc superoxide dismutase apoprotein substantially influences the structure and stability of the entire homodimeric protein

The thermodynamics of zinc binding to metal-free (apo) human and bovine copper-zinc superoxide dismutases (SOD1) were measured using isothermal titration calorimetry. The apparent thermodynamics of zinc binding to the apoproteins were favorable (Ka > 108 M-1), with an observed stoichiometry of one zinc per homodimer. The change in heat capacity for the one-zinc binding event was large and negative (approximately -650 cal mol-1 K-1), suggestive of significant structural changes to the protein upon zinc binding. We further characterized the one-zinc derivative by circular dichroism and determined that this derivative had nearly the same secondary structure as the two-zinc derivative and that both are structurally distinct from the metal-free protein. In addition, we monitored the effect of zinc binding on hydrogen-deuterium exchange and accessibility of histidyl residues to modification by diethyl pyrocarbonate and observed that more than 50% protection was afforded by the binding of one zinc in both assays. Differential scanning calorimetry on the human SOD1 zinc derivatives also showed increased thermostability of the protein due to zinc binding. Further, the melting transitions observed for the one-zinc derivative closely resembled those of the two-zinc derivative. Finally, we observed that the quaternary structure of the protein is stabilized upon binding of one and two zinc ions in analytical ultracentrifugation experiments. Combined, these results suggest communication between the two monomers of SOD1 such that the binding of one zinc ion per homodimer has a more profound effect on the homodimeric protein structure than the binding of subsequent metal ions. The relevance of these findings to amyotrophic lateral sclerosis is discussed.

Multiple isoelectric variants of copper, zinc-superoxide dismutase from rat liver

Isoelectric variants of Cu,Zn-superoxide dismutase (Cu,Zn-SOD) have been reported to exist in various organs including rat liver. To elucidate the biochemical characteristics of the variants, rat liver Cu,Zn-SOD was purified and isolated into eight variants, i.e., pI 5.15, 4.88, 4.80, 4.75, 4.70, 4.65, 4.60, and 4.50. The pI 4.88 variant had the highest specific activity (4245 U/mg protein) and the highest yield (45% of original activity). The descending order of specific activity for the other variants was pI 4.80, 4.75, 5.15, 4.70, 4.65, 4.60, and 4.50. The specific activity correlated well with metal content. The specific activity for most variants was 5-9 times greater when determined at pH 10.0 than at pH 7.8. However, three preparations of pI 4.80 and 4.70 variants had 13.9-16.3 times greater specific activity at pH 10.0 versus 7.8, while one of the pI 4.60 variants was only 3.5 times greater. The rate of Coomasie brilliant blue G-250 binding was lowest with pI 4.88 followed by pIs 4.80 and 4.75. To evaluate the mechanisms which might produce these variants, the pI 4.88 variant was incubated with xanthine-xanthine oxidase or a mixture of rat liver microsome, NADPH, and sodium azide, and a shift to variants pI 4.80 and pI 4.75 was found. The shift was greatly inhibited by the presence of mannitol or by the omitting of azide, respectively. The existence of these variants was also confirmed by other methods: (i) direct application of rat liver 105,000g supernatant to an isoelectric focusing, and (ii) extraction of SOD from acetone powder prepared from rat liver homogenate. Results indicate that several variants most likely arise in tissue as a result of activated oxygen radical modification of variant pI 4.88.

Regular trisomy 21 not accompanied by increased copper-zinc superoxide dismutase (SOD1) activity

The Cu-Zn superoxide dismutase (SOD1) activity was estimated in red blood cells in children with regular trisomy 21. We report patients displaying typical Down syndrome clinical features and with SOD1 activity in the normal range.